Ozempic Warning Label Update Adds Support to Gastroparesis Lawsuits With thousands of gastroparesis symptoms being reported to the FDA since Ozempic was introduced in 2017, officials recently released a new label warnings for Ozempic in 2023, now indicating for the first time that the drug can increase the risk of intestinal blockages, through a condition known as ileus
Over 18's only
Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures
Tian S, Jiang J, Wang J, Zhang Z, Miao Y, Ji X, et al
These processes include gene expression (how our genes behave or express themselves), and DNA synthesis (creating new DNA, which is important for cell growth and repair)
Certain individuals should avoid tirzepatide, including those with histories of pancreatitis, medullary thyroid cancer, severe gastrointestinal conditions, or allergies to GLP-1 receptor agonists